Ads
related to: stelara for crohn's disease- Patient Resources
Information About Injecting
Cost Support and More
- Cost Support Information
Learn About Cost Support Options
View Support Program Info.
- Save on STELARA®
Eligible Patients pay $5 copay/dose
2020 additional requirements apply
- About STELARA®
Information on Getting Started
Learn More About STELARA® Today
- Patient Resources
Search results
What to know about biologics for Crohn's disease
Medical News Today· 1 day agoCrohn’s disease biologics are medications created using components of living organisms. Crohn’s ...
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
Zacks via Yahoo Finance· 2 days agoWhile management had previously reported that the study VIVID-1 study achieved its co-primary...
IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
Investor's Business Daily· 3 days agoEli Lilly Stock Jumps On Crohn's Results Crohn's disease is a chronic, inflammatory bowel
J&J’s Tremfya superior to Stelara in Phase II/III Chron’s disease trials
Clinical Trials Arena via Yahoo Finance· 3 days agoApproximately 30% of people with Crohn's disease develop symptoms before the age of 20. A GlobalData...
Guselkumab Continues Winning Streak in Crohn's Disease
MedPage Today· 3 days agoInduction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy...
Johnson & Johnson shares maintain outperform rating at RBC on TREMFYA potential By Investing.com
Investing.com· 2 days agoThe company has recently filed for approval of TREMFYA as a treatment for Ulcerative Colitis in...
J&J’s Tremfya meets endpoints in Phase III ulcerative colitis trial
Clinical Trials Arena via Yahoo Finance· 3 days agoJ&J’s Tremfya is expected to be the successor to the company’s IL-12/IL-23 inhibitor Stelara...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 4 days agoS., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing ...
Alvotech (NYSE:ALVO) Releases Quarterly Earnings Results, Misses Estimates By $0.81 EPS
ETF DAILY NEWS· 16 hours agoAlvotech (NYSE:ALVO – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates ...
Ads
related to: stelara for crohn's disease
